TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

Kenichiro Kobayashi; Naoyuki Miyagawa; Kazumasa Mitsui; Masaki Matsuoka; Yasuko Kojima; Hiroyuki Takahashi; Kaori Ootsubo; Junichi Nagai; Hitomi Ueno; Takeshi Ishibashi; Sara Sultana; Yoko Okada; Shingo Akimoto; Hajime Okita; Kimikazu Matsumoto; Hiroaki Goto; Nobutaka Kiyokawa; Akira Ohara

doi:10.1002/pbc.25327

TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

Kenichiro Kobayashi, Naoyuki Miyagawa, Kazumasa Mitsui, Masaki Matsuoka, Yasuko Kojima, Hiroyuki Takahashi, Kaori Ootsubo, Junichi Nagai, Hitomi Ueno, Takeshi Ishibashi, Sara Sultana, Yoko Okada, Shingo Akimoto, Hajime Okita, Kimikazu Matsumoto, Hiroaki Goto, Nobutaka Kiyokawa, Akira Ohara

研究成果: Article › 査読

45 被引用数 (Scopus)

抄録

We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

本文言語	English
ページ（範囲）	1058-1060
ページ数	3
ジャーナル	Pediatric Blood and Cancer
巻	62
号	6
DOI	https://doi.org/10.1002/pbc.25327
出版ステータス	Published - 2015 6 1
外部発表	はい

ASJC Scopus subject areas

小児科学、周産期医学および子どもの健康
血液学
腫瘍学

文献へのアクセス

10.1002/pbc.25327

他のファイルとリンク

引用スタイル

Kobayashi, K., Miyagawa, N., Mitsui, K., Matsuoka, M., Kojima, Y., Takahashi, H., Ootsubo, K., Nagai, J., Ueno, H., Ishibashi, T., Sultana, S., Okada, Y., Akimoto, S., Okita, H., Matsumoto, K., Goto, H., Kiyokawa, N., & Ohara, A. (2015). TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediatric Blood and Cancer, 62(6), 1058-1060. https://doi.org/10.1002/pbc.25327

TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. / Kobayashi, Kenichiro; Miyagawa, Naoyuki; Mitsui, Kazumasa; Matsuoka, Masaki; Kojima, Yasuko; Takahashi, Hiroyuki; Ootsubo, Kaori; Nagai, Junichi; Ueno, Hitomi; Ishibashi, Takeshi; Sultana, Sara; Okada, Yoko; Akimoto, Shingo; Okita, Hajime; Matsumoto, Kimikazu; Goto, Hiroaki; Kiyokawa, Nobutaka; Ohara, Akira.

In: Pediatric Blood and Cancer, Vol. 62, No. 6, 01.06.2015, p. 1058-1060.

研究成果: Article › 査読

Kobayashi, K, Miyagawa, N, Mitsui, K, Matsuoka, M, Kojima, Y, Takahashi, H, Ootsubo, K, Nagai, J, Ueno, H, Ishibashi, T, Sultana, S, Okada, Y, Akimoto, S, Okita, H, Matsumoto, K, Goto, H, Kiyokawa, N & Ohara, A 2015, 'TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation', Pediatric Blood and Cancer, vol. 62, no. 6, pp. 1058-1060. https://doi.org/10.1002/pbc.25327

Kobayashi, Kenichiro ; Miyagawa, Naoyuki ; Mitsui, Kazumasa ; Matsuoka, Masaki ; Kojima, Yasuko ; Takahashi, Hiroyuki ; Ootsubo, Kaori ; Nagai, Junichi ; Ueno, Hitomi ; Ishibashi, Takeshi ; Sultana, Sara ; Okada, Yoko ; Akimoto, Shingo ; Okita, Hajime ; Matsumoto, Kimikazu ; Goto, Hiroaki ; Kiyokawa, Nobutaka ; Ohara, Akira. / TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 6. pp. 1058-1060.

@article{5be53b4faec541939592ebb27ddd3bd3,

title = "TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation",

abstract = "We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.",

keywords = "Genomic PCR, MRD, PDGFRB fusion, Ph-like ALL, TKI",

author = "Kenichiro Kobayashi and Naoyuki Miyagawa and Kazumasa Mitsui and Masaki Matsuoka and Yasuko Kojima and Hiroyuki Takahashi and Kaori Ootsubo and Junichi Nagai and Hitomi Ueno and Takeshi Ishibashi and Sara Sultana and Yoko Okada and Shingo Akimoto and Hajime Okita and Kimikazu Matsumoto and Hiroaki Goto and Nobutaka Kiyokawa and Akira Ohara",

note = "Publisher Copyright: {\textcopyright} 2014 Wiley Periodicals, Inc.",

year = "2015",

month = jun,

day = "1",

doi = "10.1002/pbc.25327",

language = "English",

volume = "62",

pages = "1058--1060",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

AU - Kobayashi, Kenichiro

AU - Miyagawa, Naoyuki

AU - Mitsui, Kazumasa

AU - Matsuoka, Masaki

AU - Kojima, Yasuko

AU - Takahashi, Hiroyuki

AU - Ootsubo, Kaori

AU - Nagai, Junichi

AU - Ueno, Hitomi

AU - Ishibashi, Takeshi

AU - Sultana, Sara

AU - Okada, Yoko

AU - Akimoto, Shingo

AU - Okita, Hajime

AU - Matsumoto, Kimikazu

AU - Goto, Hiroaki

AU - Kiyokawa, Nobutaka

AU - Ohara, Akira

PY - 2015/6/1

Y1 - 2015/6/1

N2 - We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

AB - We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

KW - Genomic PCR

KW - MRD

KW - PDGFRB fusion

KW - Ph-like ALL

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=84927911280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927911280&partnerID=8YFLogxK

U2 - 10.1002/pbc.25327

DO - 10.1002/pbc.25327

M3 - Article

C2 - 25400122

AN - SCOPUS:84927911280

VL - 62

SP - 1058

EP - 1060

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

SN - 1545-5009

IS - 6

ER -

TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

抄録

ASJC Scopus subject areas

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル